
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc. is making strides in oncology with its pipeline drug BDTX-1535, which demonstrated a 36% Overall Response Rate (ORR) in a targeted subset of non-small cell lung cancer (NSCLC) patients, showing potential for improvement to 42% after refining the patient population. The company’s unique approach to targeting non-classical EGFR mutations addresses an unmet need, providing a competitive edge as current therapies fail to adequately treat these cases. With 74% of patients remaining on treatment after an initial follow-up of 4.7 months, the encouraging initial results, combined with expected data updates from ongoing studies in 2025, suggest a viable regulatory path and growth potential for the company's stock.
Bears say
Black Diamond Therapeutics Inc faces several significant risks that contribute to a negative outlook, including potential negative efficacy data for its drug BDTX-1535 and the possibility of poor safety profiles or adverse clinical data for its pipeline candidates. The company has also adjusted its expense assumptions and commercialization timeline, resulting in a downward revision of its target price, reflecting concerns about its financial trajectory. Additionally, for the full year 2025, Black Diamond is projected to incur a net loss of $1.32 per share, further emphasizing ongoing financial instability and risk of dilution for investors.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares